Absence of effect of telbivudine on cardiac repolarization: results of a thorough QT/QTc study in healthy participants.

The effect of telbivudine on cardiac repolarization was evaluated in healthy participants at clinical and supratherapeutic doses. Sixty-two participants were enrolled, stratified by sex, and randomized according to a crossover design among 4 treatment sequences: placebo, a single moxifloxacin 400-mg dose as positive calibrator, and telbivudine 600 and 1800 mg/d for 7 days. Intensive time-matched electrocardiogram measurements and pharmacokinetic sampling were performed at baseline and on day 7 over 24 hours.

The outcome of liver grafts procured from hepatitis C-positive donors.

Background: The growing prevalence of hepatitis C virus (HCV) infection in the general population has resulted in an increased frequency of potential organ donors that carry the virus. The survival of grafts from HCV+ donors has not been studied in detail.

Methods: Two study populations were examined retrospectively to assess the survival of liver grafts procured from HCV+ donors.